Micafungin
Micafungin is an echinocandin antifungal given by IV to treat serious Candida infections (bloodstream infections, deep infections, and esophageal candidiasis) and to prevent Candida infections in people having a stem cell transplant.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 14 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
How we combine label and product data →
Patient information guide — a plain-language walkthrough of Micafungin, written from its FDA label.
What Micafungin is used for
▾
Micafungin is an IV antifungal used for the following Candida-related conditions:
- Candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses in adults and children 4 months and older.
- The same infections, without meningoencephalitis or eye involvement, in children younger than 4 months.
- Esophageal candidiasis in adults and children 4 months and older.
- Prevention of Candida infections in adults and children 4 months and older having a stem cell transplant.
- Micafungin in Sodium Chloride Injection is for use when appropriate dosing with this formulation can be achieved.
It has not been adequately studied in Candida endocarditis, osteomyelitis or meningoencephalitis. It has not been shown to work against fungi other than Candida.
How Micafungin works
▾
Micafungin is an echinocandin, a class of antifungal medicines.
Micafungin dosage
▾
Micafungin is given as an IV infusion over about 1 hour, once daily. Mycamine and the other micafungin products are prepared and given by healthcare professionals.
- Dose depends on the infection and on age and weight in children.
- Treatment length varies. In studies, successful treatment of candidemia averaged about 15 days.
- Micafungin in Sodium Chloride Injection comes in set strengths and is not recommended if a different dose is needed.
Follow your prescriber's directions. Your care team handles any missed dose.
Dosing details from the FDA-approved label
From the Micafungin prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses
- 100 mg once daily
- In patients treated successfully, the mean duration of treatment was 15 days (range 10 to 47 days)
- Adults: Treatment of Esophageal Candidiasis
- 150 mg once daily
- In patients treated successfully, the mean duration of treatment was 15 days (range 10 to 30 days)
- Adults: Prophylaxis of Candida Infections in HSCT Recipients
- 50 mg once daily
- In HSCT recipients with successful prophylaxis, the mean duration was 19 days (range 6 to 51 days)
- Pediatric patients 4 months and older, 30 kg or less: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses
- 2 mg/kg once daily
- Maximum: maximum daily dose 100 mg
- Weight 30 kg or less
- Pediatric patients 4 months and older, 30 kg or less: Treatment of Esophageal Candidiasis
- 3 mg/kg once daily
- Weight 30 kg or less
- Pediatric patients 4 months and older, greater than 30 kg: Treatment of Esophageal Candidiasis
- 2.5 mg/kg once daily
- Maximum: maximum daily dose 150 mg
- Weight greater than 30 kg
- Pediatric patients 4 months and older: Prophylaxis of Candida Infections in HSCT Recipients
- 1 mg/kg once daily
- Maximum: maximum daily dose 50 mg
- Not approved for esophageal candidiasis or prophylaxis in patients younger than 4 months
- Pediatric patients younger than 4 months: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination
- 4 mg/kg once daily
- Safety and effectiveness not established with meningoencephalitis and/or ocular dissemination, as a higher dose may be needed
Read the label’s full dosing text
Recommended Dosage Administered by Indication, Weight and Age (2.1, 2.2, 2.3, 8.4) Adult Pediatric Patients 4 Months and Older 30 kg or less Pediatric Patients 4 Months and Older greater than 30 kg Pediatric Patients Younger than 4 Months of Age Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses 100 mg daily 2 mg/kg/day (maximum 100 mg daily) See below Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without Meningoencephalitis and/or Ocular Dissemination See above See above 4 mg/kg/day Treatment of Esophageal Candidiasis 150 mg daily 3 mg/kg/day 2.5 mg/kg/day (maximum 150 mg daily) Not approved Prophylaxis of Candida Infections in HSCT Recipients 50 mg daily 1 mg/kg/day (maximum 50 mg daily) Not approved Infuse over 1 hour. (2.5) See Full Prescribing Information for intravenous (IV) preparation and administration instructions. (2) 2.1 Dosage for Adults The recommended dosage for adult patients based on indications are shown in Table 1. Table 1. Micafungin for Injection Dosage in Adult Patients Indication Recommended Reconstituted Dose Once Daily Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses * 100 mg Treatment of Esophageal Candidiasis † 150 mg Prophylaxis of Candida Infections in HSCT Recipients ‡ 50 mg *In patients treated successfully for candidemia and other Candida infections, the mean duration of treatment was 15 days (range 10 to 47 days). † In patients treated successfully for esophageal candidiasis, the mean duration of treatment was 15 days (range 10 to 30 days). ‡ In hematopoietic stem cell transplant (HSCT) recipients who experienced success of prophylactic therapy, the mean duration of prophylaxis was 19 days (range 6 to 51 days). 2.2 Dosage for Pediatric Patients 4 Months and Older The recommended dosage for pediatric patients 4 months of age and older based on indication and weight are shown in Table 2. Table 2.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Micafungin side effects
▾
Common side effects
- Diarrhea
- Nausea and vomiting
- Abdominal pain
- Fever
- Headache
- Low platelet counts (thrombocytopenia)
- Low white blood cell counts (neutropenia)
- Phlebitis (vein irritation) at the IV site
When to get medical help
- Get help right away for signs of a severe allergic reaction (anaphylaxis), such as trouble breathing, swelling or shock.
- Tell your care team about rash, itching, or facial swelling during the infusion. The infusion can be slowed.
- Report dark or red urine, unusual tiredness, or paleness. These can be signs of red blood cell breakdown (hemolysis).
- Report yellowing of the skin or eyes, or other signs of liver trouble.
- Report signs of kidney problems, such as changes in urination.
- Report severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis (reported after approval).
- Report pain, redness or swelling at the IV site.
The most common side effects in clinical trials were:
- Diarrhea
- Nausea and vomiting
- Abdominal pain
- Fever
- Low platelets and low white blood cells
- Headache
- Phlebitis at the IV site
Seek help for allergic reactions, signs of liver or kidney problems, signs of red blood cell breakdown, or severe skin reactions.
Micafungin warnings and precautions
▾
- Serious allergic reactions: anaphylaxis and shock have been reported. The infusion is stopped and treated.
- Red blood cell breakdown: hemolysis and hemolytic anemia have been reported. Your team will monitor and weigh whether to continue.
- Liver effects: abnormal liver tests, and rarely hepatitis or liver failure.
- Kidney effects: raised BUN and creatinine, and rarely kidney failure.
- Infusion and IV site reactions: rash, itching, facial swelling, and vein inflammation. These happened more with peripheral IV use.
Micafungin interactions
▾
A few medicines need monitoring when used with micafungin:
- Sirolimus: levels rose, so toxicity should be watched for and the dose lowered if needed.
- Nifedipine: levels rose, so toxicity should be watched for and the dose lowered if needed.
- Itraconazole: levels rose, so toxicity should be watched for and the dose lowered if needed.
- Cyclosporine, tacrolimus, prednisolone, voriconazole, fluconazole, rifampin, ritonavir, mycophenolate and amphotericin B did not change micafungin levels or were not affected by it in studies.
Interactions listed in the FDA-approved label
From the Micafungin prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Sirolimus: Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state micafungin compared with sirolimus alone. Monitor for sirolimus toxicity; reduce the sirolimus dosage if necessary.
- Nifedipine: Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state micafungin. Monitor for nifedipine toxicity; reduce the nifedipine dosage if necessary.
- Itraconazole: Itraconazole AUC and Cmax were increased by 22% and 11%, respectively. Monitor for itraconazole toxicity; reduce the itraconazole dosage if necessary.
- Cyclosporine, voriconazole, fluconazole (CYP3A4, CYP2C9, CYP2C19 inhibitors): Co-administration did not alter the pharmacokinetics of micafungin; micafungin had no effect on cyclosporine, voriconazole and fluconazole pharmacokinetics.
- Rifampin and ritonavir (CYP2C19 and CYP3A4 inducers): Co-administration did not alter the pharmacokinetics of micafungin.
- Mycophenolate mofetil (MMF): Co-administration did not alter the pharmacokinetics of micafungin or of MMF.
- Amphotericin B: Co-administration did not alter the pharmacokinetics of micafungin.
- Tacrolimus: Co-administration did not alter the pharmacokinetics of micafungin, and micafungin had no effect on tacrolimus pharmacokinetics.
- Prednisolone: Co-administration did not alter the pharmacokinetics of micafungin, and micafungin had no effect on prednisolone pharmacokinetics.
Read the label’s full interactions text
7 DRUG INTERACTIONS Monitor for sirolimus, itraconazole or nifedipine toxicity, and dosage of sirolimus, itraconazole or nifedipine should be reduced, if necessary. (7 ) 7.1 Effect of Other Drugs on Micafungin for Injection CYP3A4, CYP2C9 and CYP2C19 Inhibitors Co-administration of micafungin for injection with cyclosporine, itraconazole, voriconazole and fluconazole did not alter the pharmacokinetics of micafungin for injection. CYP2C19 and CYP3A4 Inducer Co-administration of micafungin for injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin for injection. Co-administration of Micafungin for Injection with Other Drugs Co-administration of micafungin for injection with mycophenolate mofetil (MMF), amphotericin B, tacrolimus, prednisolone, sirolimus and nifedipine did not alter the pharmacokinetics of micafungin for injection. 7.2 Effect of Micafungin for Injection on Other Drugs CYP3A4 Substrates There was no effect of single or multiple doses of micafungin for injection on cyclosporine, tacrolimus, prednisolone, voriconazole and fluconazole pharmacokinetics. Sirolimus AUC was increased by 21% with no effect on C max in the presence of steady-state micafungin for injection compared with sirolimus alone. Nifedipine AUC and C max were increased by 18% and 42%, respectively, in the presence of steady-state micafungin for injection compared with nifedipine alone. Itraconazole AUC and C max were increased by 22% and 11%, respectively. Patients receiving sirolimus, nifedipine, and itraconazole in combination with micafungin for injection should be monitored for sirolimus, nifedipine, and itraconazole toxicity and the sirolimus, nifedipine, and itraconazole dosage should be reduced if necessary. UDP-Glycosyltransferase Substrate Co-administration of mycophenolate mofetil (MMF) with micafungin for injection did not alter the pharmacokinetics of MMF.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Micafungin
▾
- Do not use it if you are allergic to micafungin or other echinocandins.
- Pregnancy: animal data show it may cause fetal harm. Discuss with your doctor.
- Breastfeeding: there are no human data. Your doctor will weigh the benefits and risks.
- Children: use is established from 4 months of age for most uses. Safety for meningoencephalitis in children under 4 months is not established.
- Older adults: no dose adjustment is needed.
- Kidney impairment: no dose adjustment is needed.
- Liver problems: tell your doctor, since liver effects can occur.
Micafungin overdose
▾
No cases of overdose have been reported. In clinical trials, daily doses well above the usual range were given without reported dose-limiting toxicity. Micafungin is highly protein bound, so dialysis does not remove it.
How your body processes Micafungin
▾
About 85% of steady-state levels are reached after three daily doses. The half-life is roughly 13 to 17 hours in adults. Micafungin is more than 99% bound to proteins, mainly albumin, and is broken down in the body into metabolites. Most elimination is through the feces. Kidney impairment does not require a dose change, and dialysis does not remove it.
How to store Micafungin
▾
Unopened vials of lyophilized material must be stored at room temperature, 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). Store the reconstituted product at 20° to 25°C (68° to 77°F) . Store the diluted solution at 20° to 25°C (68° to 77°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Micafungin: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Micafungin — the kind of thing our pharmacy team would talk through with you at the counter.
What is micafungin used for?
▾
How is it given?
▾
What side effects should I expect?
▾
When should I call for help?
▾
Does it interact with my other medicines?
▾
Is it safe during pregnancy?
▾
Is Micafungin available over the counter?
▾
When was Micafungin first available?
▾
Who makes Micafungin?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Micafungin on HelloPharmacist
Micafungin forms and strengths (how it comes)
Micafungin is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Micafungin in Sodium Chloride Injection is used for Candida bloodstream and deep infections, esophageal candidiasis, and prevention of Candida infection in stem cell transplant, when appropriate dosing with this formulation can be achieved.
- Mycamine is used for Candida bloodstream and deep infections, esophageal candidiasis, and prevention of Candida infection in stem cell transplant.
- Micafungin for Injection is used for the same Candida infections and for prevention in stem cell transplant.
- Mycamine is given by IV infusion over 1 hour.
- Micafungin in Sodium Chloride Injection is given by IV infusion over 1 hour.
- Micafungin in Sodium Chloride Injection is not recommended if the needed dose is not 50 mg, 100 mg or 150 mg. Another micafungin formulation should be considered.
Show 3 more strengths Show fewer strengths
Micafungin on the U.S. market: products, makers and brands
How Micafungin appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
28 companies list 81 Micafungin product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2005. Brand names on the directory include Mycamine, Micafungin in Sodium Chloride; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (12) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Micafungin is used (Medicaid data)
A general measure of how commonly Micafungin is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Micafungin is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Micafungin prescribed? Of the 1,600 medications we measure, Micafungin ranks #958 by Medicaid prescriptions — more than 40% of them.
Utilization by Micafungin product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
micafungin 100 MG Injection Most dispensed
Summed across the 10 of 32 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 861383
micafungin 50 MG Injection
Summed across the 8 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 861379
100 ML micafungin 1 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2667650
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Micafungin, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 19 of 63 listed Micafungin NDCs with Medicaid activity.
Compare Micafungin products
A representative set of FDA-listed product records for Micafungin — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 10 mg/mL | Intravenous | Apotex Corp. × 2 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Apotex Corp. × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Astellas Pharma US, Inc. × 2 listings | NDA | View NDC → |
| 20 mg/mL | Intravenous | Astellas Pharma US, Inc. × 2 listings | NDA | View NDC → |
| 50 mg/50 mL | Intravenous | Baxter Healthcare Corporation × 3 listings | NDA | View NDC → |
| 100 mg/100 mL | Intravenous | Baxter Healthcare Corporation × 3 listings | NDA | View NDC → |
| 150 mg/150 mL | Intravenous | Baxter Healthcare Corporation × 3 listings | NDA | View NDC → |
| 10 mg/mL | Intravenous | Biocon Pharma Inc. | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Biocon Pharma Inc. | ANDA | View NDC → |
| 100 mg | Intravenous | Civica, Inc. × 2 listings | ANDA | View NDC → |
| 50 mg | Intravenous | Fresenius Kabi USA, LLC × 2 listings | ANDA | View NDC → |
| 100 mg | Intravenous | Fresenius Kabi USA, LLC × 4 listings | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 50 mg | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 100 mg | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 50 mg | Intravenous | Hisun Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 100 mg | Intravenous | Hisun Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 50 mg/5 mL | Intravenous | Meitheal Pharmaceuticals Inc. × 3 listings | ANDA | View NDC → |
| 100 mg/5 mL | Intravenous | Meitheal Pharmaceuticals Inc. × 3 listings | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Northstar Rx LLC. × 2 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Northstar Rx LLC. × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Par Health USA, LLC | NDA | View NDC → |
| 20 mg/mL | Intravenous | Par Health USA, LLC | NDA | View NDC → |
| 10 mg/mL | Intravenous | Par Pharmaceutical, Inc. × 2 listings | NDA | View NDC → |
| 20 mg/mL | Intravenous | Par Pharmaceutical, Inc. × 2 listings | NDA | View NDC → |
| 10 mg/mL | Intravenous | Qilu Pharmaceutical Co., Ltd | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Qilu Pharmaceutical Co., Ltd | ANDA | View NDC → |
| 50 mg/5 mL | Intravenous | Sagent Pharmaceuticals × 2 listings | ANDA | View NDC → |
| 100 mg/5 mL | Intravenous | Sagent Pharmaceuticals × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Xellia Pharmaceuticals USA LLC × 2 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Xellia Pharmaceuticals USA LLC × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Zydus Lifesciences Limited × 2 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Zydus Lifesciences Limited × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Zydus Pharmaceuticals USA Inc. × 2 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Zydus Pharmaceuticals USA Inc. × 2 listings | ANDA | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Biocon limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | BrightGene Bio-Medical Technology Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 mg/mg | — | Concord Biotech Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Hetero Drugs Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. × 3 listings | BULK INGREDIENT | View NDC → |
| 75 kg/75 kg | — | Medichem Manufacturing (Malta) Ltd. | BULK INGREDIENT | View NDC → |
| 75 kg/75 kg | — | Medichem S.A. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | MSN Life Sciences Private Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Yung Shin Pharm. Ind. Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Zhejiang Hisun Pharmaceutical Co., Ltd. | BULK INGREDIENT | View NDC → |
Showing 81 of 81 products — FDA National Drug Code Directory. See every product, package size and price: browse all 81 Micafungin NDCs →
Micafungin side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Micafungin — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Micafungin in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Micafungin FDA approval history
How Micafungin went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Micafungin recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Micafungin recalls since July 2021.
✅No Micafungin recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 325887 1 dose form · 5 strengths
-
Dose form (SCDF) Injection RxCUI 1722943In current FDA listingsClinical drug / strength (SCD) 50 MGRxCUI 86137950 ML micafungin 1 MG/MLRxCUI 2667653100 MGRxCUI 861383100 ML micafungin 1 MG/MLRxCUI 2667650150 ML micafungin 1 MG/MLRxCUI 2667652
Look up RxCUI 325887 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Micafungin supply and shortage status
Whether Micafungin is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Micafungin brand names
Micafungin is sold under 2 brand names in the FDA directory — Mycamine, Micafungin in Sodium Chloride. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Micafungin: manufacturers and labelers
28 companies list Micafungin products with the FDA. By number of product records, the largest are Baxter Healthcare Corporation, Fresenius Kabi USA, LLC, Meitheal Pharmaceuticals Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 4 more on the FDA NDC directory.
Micafungin drug class (RxNorm)
Micafungin belongs to the Echinocandin Antifungal class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Micafungin page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Par Pharmaceutical, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →